Previous 10 |
Lumen Bioscience Announces Appointment of Dr. Mark Litton to Board of Directors PR Newswire SEATTLE, Oct. 8, 2020 SEATTLE , Oct. 8, 2020 /PRNewswire/ -- Lumen Bioscience , a clinical-stage biopharmaceutical company developing biologic drugs for highly pr...
Athira Pharma (ATHA) has commenced patient dosing in Phase 2/3 trial (LIFT-AD) evaluating ATH-1017 for the treatment of mild-to-moderate Alzheimer's disease.The 300-subject trial conducted in the U.S. and Australia, will evaluate the safety and efficacy of ATH-1017. Clinical efficacy wil...
- Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to- moderate Alzheimer’s disease - SEATTLE, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused ...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...